Theseus Pharmaceuticals
  • Contact
  • Company
    • About Us
    • Leadership
    • Contact
  • Science
    • Our Approach
    • Disease Focus
    • Publications & Posters
  • Pipeline
    • Pipeline
    • KIT Program for GIST
    • EGFR Program for NSCLC
    • Discovery Program
    • Expanded Access Policy
  • Join Us
    • Our Culture
    • Open Roles
    • Diversity Commitment
  • Investors & Media
    • Corporate Profile
    • News & Events
      • News Releases
      • Events
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • SEC Filings
    • Corporate Governance
      • Corporate Governance
      • Leadership Team
      • Board of Directors
      • Board Committees
    • Investor Resources
      • Investor FAQs
      • Investor Alerts
Select Page
Theseus Pharmaceuticals
    • Company
      • About Us
      • Leadership
      • Contact
    • Science
      • Our Approach
      • Disease Focus
      • Publications & Posters
    • Pipeline
      • Pipeline
      • KIT Program for GIST
      • EGFR Program for NSCLC
      • Discovery Program
      • Expanded Access Policy
    • Join Us
      • Our Culture
      • Open Roles
      • Diversity Commitment
    • Investors & Media
      • Corporate Profile
      • News & Events
        • News Releases
        • Events
      • Stock Information
        • Stock Quote & Chart
        • Historical Price Lookup
      • SEC Filings
      • Corporate Governance
        • Corporate Governance
        • Leadership Team
        • Board of Directors
        • Board Committees
      • Investor Resources
        • Investor FAQs
        • Investor Alerts
Header_Image_Investors
SEC Filings
Theseus Pharmaceuticals
YearTrailing 12-MonthsCalendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2018
ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
DOfficial notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the ActJun 29, 2018Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in HTML.Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in DOC file.Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in PDF file.Open Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act in XLS file.
Media Contact

Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com

Investor Contact

Christen Baglaneas
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

Footer logo

Company

  • About Us
  • Leadership
  • Contact

Science

  • Our Approach
  • Disease Focus
  • Publications & Posters

Programs

  • Pipeline
  • KIT Program
  • EGFR Program
  • Discovery Program
  • Expanded Access Policy

Join Us

  • Our Culture
  • Open Roles
  • Diversity Commitment

Investors

  • Corporate Profile
  • News & Events
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Resources
Footer logo
© 2023 Theseus Pharmaceuticals. All rights reserved.
  • Privacy Policy
  • Terms of Use